Heart Failure

This heart failure channel offers news and new technology to treat heart failure. This includes for new innovations to treat congestive heart failure (CHF). The channel includes news on HFpEF and HFrEF. Heart failure occurs when the heart is no longer able to pump as much blood as the body requires. This can lead to enlargement of the heart because the muscle works harder to supply blood, but the pumping is ineffective. This may be due to defects in the myocardium, such as an infarct, or due to structural issues such as severe valve regurgitation. The disease is divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or a left ventricular assist device (LVAD).

News | Heart Failure

Study Shows Heart Failure Treatment With Dapagliflozin Consistently Benefited Both Men and Women

November 14, 2022 — When it comes to heart failure (HF), sex differencesare known to impact everything from risk factors ...

November 14, 2022

Reduction in the risk of death or major bleeding after primary PCI in patients with STEMI treated with heparin monotherapy (blue curve) or bivalirudin with a post-procedure infusion (red curve). The hazard ratio of 0.69 signifies a 31% reduction in risk. The ARR (absolute risk reduction) was 1.3%. The NNT (number of patients needed to treat to prevent one death or large bleed) was 76. Image courtesy of Mount Sinai Health System

News | Antiplatelet and Anticoagulation Therapies

Bivalirudin Found to be Safer and More Effective Than Heparin for Treating Heart Attack Patients Undergoing Percutaneous Coronary Intervention

November 14, 2022 — Bivalirudin is a safer and more effective anticoagulant than heparin for treating patients with the ...

November 14, 2022

The "Trending Topics at Sessions 2022" panel of experts featured Manesh R. Patel, MD, FACC, FAHA, Chair of the Committee on AHA 2022 Scientific Sessions, to review highlights and lessons learned from the event.

News | AHA

November 14, 2022 — The American Hospital Association Scientific Sessions 2022, held Nov. 5-7 in Chicago, IL, presented ...

November 14, 2022

Sponsored Content

Blog | Artificial Intelligence

BLOG: AI outperforms human analysis in predicting cardiac outcomes

New research shows superiority of Ultromics’ AI in predicting cardiac-related death As the use of artificial ...

October 10, 2022

Risk Reductions of 46% to 52% for Heart Failure Readmissions and for Composite of CV Death and Heart Failure Readmissions at 30- and 90-Days Following Hospital Discharge

News | Heart Failure

New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin’s Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure

November 9, 2022 — Lexicon Pharmaceuticals, Inc. announced that a new analysis of results from the SOLOIST-WHF Phase 3 ...

November 09, 2022

Robert J. Mentz, M.D., Associate Professor of Medicine, Chief, Heart Failure Section, Associate Program Director, Duke Cardiology Fellowship, Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, image copyright Robert J. Mentz

News | AHA

TRANSFORM-HF Trial Found No Difference in Effectiveness Between 2 Common Loop Diuretics

November 8, 2022 — After hospital discharge for heart failure, people treated with either loop diuretic medication ...

November 08, 2022

Julian D. Gillmore, M.D., Ph.D., Professor, University College London Centre for Amyloidosis, United Kingdom, image copyright University College London Centre for Amyloidosis

News | AHA

Novel Gene-Editing Therapy Shows Promise For Patients With Transthyretin Amyloid Cardiomyopathy

November 8, 2022 — A single IV infusion of NTLA-2001, a novel CRISPR/Cas9-based gene editing therapy, significantly ...

November 08, 2022

New guidance covers recommendations for surgery, imaging, family screening, and the importance of a multidisciplinary team

News | ACC

AHA and ACC Issue New Guideline on Aortic Disease

Nov. 4, 2022 — The American College of Cardiology and the American Heart Association have published a new guideline on ...

November 05, 2022

Fig. 1. Selective reduction of succinyl-CoA among the TCA cycle metabolites in cardiac muscle during chronic HF. Relative levels of the TCA cycle metabolites in cardiac muscles isolated from myocardial infarction (MI) mice, compared with those from sham mice, 28 d after surgery. Each data point in the dot plot represents one individual mouse sample (n = 38 for both groups for all metabolites, except for succinyl-CoA in which n = 18 for both groups). Concentrations of succinyl-CoA in these samples were 2.2–5

News | Heart Failure

How Heart Failure Disrupts the Cell's Powerhouse

November 3, 2022 — Chronic heart failure causes the cell’s powerhouses to dysfunction, in part due to overconsumption of ...

November 03, 2022

About one-fifth of implants of left ventricular-assist devices have the complication of right heart failure. Abbott Laboratories (adapted)

News | Ventricular Assist Devices (VAD)

Study Sifts Potential Factors of Device-Implant Complication

November 2, 2022 — For decades, left ventricular-assist devices (LVADs) have extended the lives of people whose hearts ...

November 02, 2022

Impella RP Flex with SmartAssist Illustration (Photo: Business Wire)

News | Hemodynamic Support Devices

Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure

November 1, 2022 — Abiomed announced that Impella RP Flex with SmartAssist has received U.S. Food and Drug ...

November 01, 2022

Feature | Cardiovascular Business | By Melinda Taschetta-Millane

Top 10: What Viewers Were Reading in October

Here is what you and your colleagues found to be most interesting in the fields of diagnostic and interventional ...

November 01, 2022

Patent builds on previously granted U.S. patent as well as strengthens and diversifies the IP portfolio and further protects future revenues

News | ECG

HeartSciences Granted European Patent for Proprietary Electrode and Cable Connections for Use with its AI-Based MyoVista ECG

October 28, 2022 — Heart Test Laboratories, Inc., a medical technology company focused on saving lives by making an ECG ...

October 28, 2022

The RELIEVE-HF trial of the Ventura Shunt System includes patients with reduced and preserved left ventricular function etiologies for heart failure

News | Heart Failure

V-Wave Completes Enrollment in the RELIEVE-HF Randomized Double-Blind Controlled Trial of Interatrial Shunting for Heart Failure

October 28, 2022 — V-Wave, announced today the completion of enrollment in RELIEVE-HF, a prospective, randomized ...

October 28, 2022

Barostim Baroreflex Activation Therapy is the world’s first FDA-approved device which uses the power of the brain and nervous system to improve symptoms of progressive heart failure

News | Heart Failure

Allegheny Health Network Cardiovascular Institute First in Pittsburgh to Implant Groundbreaking Neuromodulation Device as Alternative Therapy for Heart Failure Patients

October 27, 2022 — Vascular surgeons from Allegheny General Hospital (AGH) Cardiovascular Institute, the flagship ...

October 27, 2022

The research team members say they have long known that infections such as the flu can increase risk for heart disease and heart attack, but the sharp rise in heart attack deaths is like nothing seen before.

News | Coronavirus (COVID-19)

COVID-19 Surges Linked to Spike in Heart Attacks

October 27, 2022 — New data analysis from the Smidt Heart Institute at Cedars-Sinai found that deaths from heart ...

October 27, 2022